Posted by Michael Wonder on 31 Mar 2022
New Zealand Pharmaceutical Schedule -1 April 2022
1 April 2022 - The April 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.
There are a few new listings of note this month.
There are minor restriction changes for the following medicines some of which are now no longer patent protected:
- Abiraterone acetate (Zytiga)
- Erlotinib hydrochloride (Tarceva)
- Gefitinib (Iressa)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Sunitinib maleate (Sutent)
- Rituximab (Riximyo)
- Zoledronic acid monohydrate (Aclasta, Zoledronic Acid Mylan)
